Oxford BioDynamics, UK-based company focused on the discovery and development of novel epigenetic biomarkers, has appointed Martin Reeves as Senior Vice President of Commercial Development. Martin will be based in the US and will take up this role in March 2017.
Martin has more than 20 years’ experience in business development and strategic planning, including Teva Pharmaceuticals where he was Head of Business Development for Global Branded Products.
He was previously Vice President of Business Development and Strategic Planning at Cephalon where, in his 14 years at the company, he played a key role in defining the strategic direction for growth and diversification globally, including planning strategies to enter into new markets such as Asia. Cephalon was bought by Teva in 2011 for $6.8bn.
Prior to joining Cephalon, Martin held project management roles at Wyeth-Ayerst and Smith Kline Beecham. Martin started his career as a Research Biochemist at Smith Kline & French and holds a degree in Biochemistry from London University.
Christian Hoyer Millar, CEO of Oxford BioDynamics said:
“Martin's considerable experience in business development within the sector will be a great asset to Oxford BioDynamics as we look to leverage IP licensing opportunities with our award-winning, proprietary technology platform, EpiSwitch.”
